Trial Profile
A PHASE I/II EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH RECURRENT OR METASTATIC NON-NASOPHARYNGEAL HEAD AND NECK CANCER
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 May 2011
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 20 May 2011 New trial record